Nasdaq

Hoth Completes Animal Safety Study of Proprietary BioLexa Platform for the Treatment of Atopic Dermatitis

NEW YORK, Jan. 21, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company focused on developing new generation therapies for dermatological and immunological ...
Benzinga.com

Hoth Therapeutics Reports Finishing Up a Busy Year of Research Across its Portfolio of Drug Candidates

The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Hoth Therapeutics HOTH is a clinical-stage ...
Nasdaq

Hoth Therapeutics, Inc., Voltron Therapeutics, Inc., & HaloVax Announce Selection of the First of Two Sets of Virus Targeting Peptides for Animal Testing in the Development of ...

NEW YORK, April 24, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (Nasdaq: HOTH) announced today that Voltron Therapeutics, Inc has selected the peptides required to complete the structure of HaloVax ...
Benzinga.com

EXCLUSIVE: Hoth Therapeutics Gives Cannabinoid-Based Lupus Candidate Back To Zylö

Hoth Therapeutics Inc (NASDAQ:HOTH) has agreed to license its cannabinoid therapeutic, HT-005, for lupus patients back to Zylö Therapeutics. What Happened: In August 2019, Hoth Therapeutics and Zylö ...